122 related articles for article (PubMed ID: 18157857)
1. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.
Takamatsu K; Takano A; Yakushiji N; Morishita K; Matsuura N; Makishima M; Ali HI; Akaho E; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 Mar; 3(3):454-60. PubMed ID: 18157857
[TBL] [Abstract][Full Text] [Related]
2. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
[TBL] [Abstract][Full Text] [Related]
3. Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity.
Morishita K; Yakushiji N; Ohsawa F; Takamatsu K; Matsuura N; Makishima M; Kawahata M; Yamaguchi K; Tai A; Sasaki K; Kakuta H
Bioorg Med Chem Lett; 2009 Feb; 19(3):1001-3. PubMed ID: 19095448
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of benzofused heterocyclic RXR modulators.
Gernert DL; Neel DA; Boehm MF; Leibowitz MD; Mais DA; Michellys PY; Rungta D; Reifel-Miller A; Grese TA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2759-63. PubMed ID: 15125928
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Ohsawa F; Yamada S; Yakushiji N; Shinozaki R; Nakayama M; Kawata K; Hagaya M; Kobayashi T; Kohara K; Furusawa Y; Fujiwara C; Ohta Y; Makishima M; Naitou H; Tai A; Yoshikawa Y; Yasui H; Kakuta H
J Med Chem; 2013 Mar; 56(5):1865-77. PubMed ID: 23391145
[TBL] [Abstract][Full Text] [Related]
6. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
7. Novel retinoid X receptor (RXR) antagonists having a dicarba-closo-dodecaborane as a hydrophobic moiety.
Ohta K; Iijima T; Kawachi E; Kagechika H; Endo Y
Bioorg Med Chem Lett; 2004 Dec; 14(23):5913-8. PubMed ID: 15501068
[TBL] [Abstract][Full Text] [Related]
8. Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXRα, RXRβ, and RXRγ.
Adouvi G; Isigkeit L; López-García Ú; Chaikuad A; Marschner JA; Schubert-Zsilavecz M; Merk D
J Med Chem; 2023 Jan; 66(1):333-344. PubMed ID: 36533416
[TBL] [Abstract][Full Text] [Related]
9. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
[TBL] [Abstract][Full Text] [Related]
10. RXR agonists inhibit high-glucose-induced oxidative stress by repressing PKC activity in human endothelial cells.
Chai D; Wang B; Shen L; Pu J; Zhang XK; He B
Free Radic Biol Med; 2008 Apr; 44(7):1334-47. PubMed ID: 18206668
[TBL] [Abstract][Full Text] [Related]
11. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
12. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
13. 3D-pharmacophore model for RXR(gamma) agonists.
Dong A; Wei J; Gao Q
Neurochem Int; 2009; 54(5-6):286-91. PubMed ID: 19121355
[TBL] [Abstract][Full Text] [Related]
14. Fundamental studies of adrenal retinoid-X-receptor: Protein isoform, tissue expression, subcellular distribution, and ligand availability.
Cheng B; Al-Shammari FH; Ghader IA; Sequeira F; Thakkar J; Mathew TC
J Steroid Biochem Mol Biol; 2017 Jul; 171():110-120. PubMed ID: 28267642
[TBL] [Abstract][Full Text] [Related]
15. RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.
Kawata K; Morishita K; Nakayama M; Yamada S; Kobayashi T; Furusawa Y; Arimoto-Kobayashi S; Oohashi T; Makishima M; Naitou H; Ishitsubo E; Tokiwa H; Tai A; Kakuta H
J Med Chem; 2015 Jan; 58(2):912-26. PubMed ID: 25486327
[TBL] [Abstract][Full Text] [Related]
16. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.
Grubbs CJ; Lubet RA; Atigadda VR; Christov K; Deshpande AM; Tirmal V; Xia G; Bland KI; Eto I; Brouillette WJ; Muccio DD
Carcinogenesis; 2006 Jun; 27(6):1232-9. PubMed ID: 16344269
[TBL] [Abstract][Full Text] [Related]
18. Advances in drug design with RXR modulators.
Vaz B; de Lera ÁR
Expert Opin Drug Discov; 2012 Nov; 7(11):1003-16. PubMed ID: 22954251
[TBL] [Abstract][Full Text] [Related]
19. Diarylamines incorporating hexahydrophenalene or octahydrobenzoheptalene as retinoid X receptor (RXR)-specific agonists.
Amano Y; Noguchi M; Shudo K
Chem Pharm Bull (Tokyo); 2014; 62(3):254-9. PubMed ID: 24583779
[TBL] [Abstract][Full Text] [Related]
20. Integrities of A/B and C domains of RXR are required for rexinoid-induced caspase activations and apoptosis.
Qin S; Okawa Y; Atangan LI; Brown G; Chandraratna RA; Zhao Y
J Steroid Biochem Mol Biol; 2008 Nov; 112(1-3):25-31. PubMed ID: 18761406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
